65,437 trials
Healthy
Primary: AUC (0-tz) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) — 6260; 6360 ng*h/mL…
Multiple Myeloma and Plasma Cell Neoplasm
Primary: 6B Antibody Response to Prevnar Vaccine in Peripheral Blood — 3.69; 7.58 fold change
Sedation · Pain
Primary: Area Under the Plasma Concentration-time Curve (AUC0-∞) — 4639.17; 14203.544 picogram*hour per millilitre
Chronic Kidney Disease Stage 5 (Dialysis Dependent)
Primary: Ability to Maintain Hemoglobin Level — 82.7; 82.6 percentage of participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks — -1.73; -1.33; -1.16 percentage of HbA1c
Epilepsy · Bone Loss · Osteoporosis
Primary: Changes in Bone Mineral Density — 1.025; 0.999; 1.332; 1.245 g/cm2
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) 24 Weeks After End of Treatment — 83.3 percentage of participants — p=0.8333
Lung Cancer
Primary: Early and Intermediate Toxicity for Dose Limiting Toxicity — 0; 0; 0; 0 participants
Sickle Cell Disease
Primary: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide — 17.56; 32.95 μg/mL
Social Anxiety Disorder
Primary: Social Phobic Disorders Severity and Change Form — 2.68; 2.95 Units on a scale
Mucositis · Multiple Myeloma
Primary: Incidence of Oral Mucositis — 66; 10; 64 percentage of participants
Gall Stone Disease · Polyp
Primary: Duration of Operation — 36.56; 30.75 minutes
Post Operative Ileus
Primary: Post-Operative Hospital Stay — 79.93; 72.94 hours — p=0.665
Bladder Cancer
Primary: Success Rate of Ultrasound-guided Obturator Nerve Block With US-IFI Group and US-NS Group — 25; 31; 6; 0 participants
Atrial Fibrillation · Stroke
Primary: Quality of Life RAND 36-Item Health Survey — 33; 46.25; 49.5; 49.16 units on a scale — p=0.03